Navigation Links
Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
Date:9/2/2013

ticipates that it will be required to conduct at least one confirmatory Phase III clinical trial of tirasemtiv in ALS patients which will require significant additional funding, and it may be unable to obtain such additional funding on acceptable terms, if at all; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Amgen's and Astellas' decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil and CK-2127107, respectively; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; Cytokinetics may be unable to enter into future collaboration agreements for its drug candidates and programs on acceptable terms, if at all; standards of care may change, rendering Cytokinetics' drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, includ
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amgen To Participate At Citis 8th Annual Biotech Conference
2. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
3. Amgen to Highlight New Data at Upcoming ESC Congress 2013
4. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
5. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
6. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
7. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
8. Amgen Announces Webcast of 2013 Second Quarter Financial Results
9. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
10. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
11. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Profil Institute for Clinical Research, Inc., a clinical research ... a new textbook,  Translational Research Methods for Diabetes, Obesity ... global scientific publisher. The textbook is the ... in early phase clinical studies of new drugs for ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has ... Market by Product, Application, Technology, End User - Global ... The infectious disease diagnostics market is expected ... million by 2019 from $12,422.8 million in 2014. Increase ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) ... by Allergen Source, Product & by End User - Global ... The global allergy diagnostics market is valued at $1,228.58 ... CAGR of 12.67%, to reach $2,230.72 million by 2019. Allergy ...
Breaking Medicine Technology:New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... May 2, 2011 Henry Schein, Inc., (NASDAQ: ... services to office-based practitioners, announced today that Stanley ... and Steven Paladino, the Company,s Executive Vice President and Chief ... Health Care Conference on May 4, 2011. The conference is ...
... Spain, May 2, 2011 Grifols, S.A. ("Grifols") and ... have signed a "Consent Agreement" with the Staff of ... Commission (FTC) by means of which the conditions for ... Consent Agreement is subject to approval of the FTC ...
Cached Medicine Technology:Henry Schein to Present at Deutsche Bank 36th Annual Health Care Conference 2Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff 2Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff 3Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff 4Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff 5
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... The Health Ethics Trust, a Division of the Council ... Compliance program an unconditional three-year certification effective October 5, ... month intensive review of the NHS program which included ... of highly respected compliance experts from around the country ...
... Hamilton, ON (Oct. 14, 2009) When people travel, bacteria ... billion people cross international borders each year, many more billions ... However, the trend is contributing to substantial domestic and international ... more recently with the H1N1 flu virus. In a ...
... prevent fever at shot time could be counterproductive, researchers say ... vaccination is a normal and essential part of building ... in the U.S. as Tylenol -- after a shot could ... vaccines, transient fever means that a child,s immune system is ...
... ... Suzanne Somers’ new book. , ... Potomac, MD (PRWEB) October 15, 2009 — Julian Whitaker, MD, has the distinct honor ... Curing Cancer and How to Prevent Getting It In the First Place. The book highlights ...
... Inc., today announced that Grant Asay has been promoted ... specialty acute care hospital system. As executive vice president ... quality of care and governance of all LifeCare hospitals. ... with more than 22 years experience. He joined LifeCare ...
... HARBIN, China, Oct. 15 /PRNewswire-Asia-FirstCall/-- SOKO Fitness ... today reported the,operating results for the first quarter of ... revenue grew 50% to $6.43 million from $4.28 million ... first quarter grew 68% to $2.43,million and fully diluted ...
Cached Medicine News:Health News:Paradigm shift needed to combat drug resistance 2Health News:Acetaminophen May Weaken Effectiveness of Kids' Vaccines 2Health News:Dr. Julian Whitaker Pens Forward for Suzanne Somers' New Cancer Book 2Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 2Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 3Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 4Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 5Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 6Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 7
ISI Alumi-Hand is the safe, sterile, ready-to-use ,surgical hand immobilizer....
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
ISI Ultra-Light Specialty Table offers the ultimate accessibility for surgeons, technicians and equipment during upper extremity surgeries....
MagPrep® Streptavidin Beads are encapsulated super-paramagnetic polystyrol particles coated with streptavidin. The beads have a diameter of 1 m and are provided as a stabilized aqueous suspensio...
Medicine Products: